Fabtech Technologies FY26 Income Surges 28% to ₹431 Cr; Order Book Tops ₹900 Cr

INDUSTRIAL-GOODSSERVICES
Whalesbook Corporate News Logo
AuthorSimar Singh|Published at:
Fabtech Technologies FY26 Income Surges 28% to ₹431 Cr; Order Book Tops ₹900 Cr
Overview

Fabtech Technologies reported robust FY26 results with total income up 28.4% to ₹431.33 Cr and an order book exceeding ₹900 Cr. The company saw a swing to positive operating cash flow and reduced debt, driven by strategic project wins in Saudi Arabia and Africa, and expansion in the animal health segment.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Fabtech Technologies FY26 Revenue Surges 28% to ₹431 Cr on Strong Order Book

Fabtech Technologies Ltd reported a significant 28.4% year-on-year jump in total income for FY26, reaching ₹431.33 crore.
The company bolstered its future revenue visibility with a robust consolidated order book exceeding ₹900 crore as of March 31, 2026.

Reader Takeaway: Revenue soared on global project wins; execution risks remain amidst market volatility.

What just happened (today’s filing)

Fabtech Technologies announced strong financial results for the fiscal year ended March 31, 2026.

Total income surged by 28.4% year-on-year to ₹431.33 crore. This growth was complemented by a healthy consolidated order book standing at over ₹900 crore as of March 31, 2026.

Operationally, the company achieved a significant turnaround, swinging to positive operating cash flow of ₹0.48 crore in FY26 from a negative ₹36.15 crore in FY25.

Further strengthening its balance sheet, current borrowings were reduced to ₹42.20 crore from ₹54.09 crore in the previous fiscal year.

Why this matters

The results highlight Fabtech's successful execution of its growth strategy, focusing on complex, high-value projects.

Expansion into high-growth geographies like Saudi Arabia and Africa, alongside diversification into the animal health segment, are key drivers for future revenue streams.

The company's emphasis on in-house manufacturing capabilities is expected to enhance project execution efficiency and profitability.

The backstory (grounded)

Fabtech Technologies has been actively expanding its international footprint, securing key contracts in strategic regions. [cite:groundedResearch.backstory[0]]

These include a USD 7.05 million OSD Facility project in West Africa and a USD 7.8 million Animal Vaccine project in Saudi Arabia. [cite:groundedResearch.backstory[0]]

A significant veterinary facility project in North Africa, valued between ₹49–52 crore, is also part of this international push. [cite:groundedResearch.backstory[0]]

What changes now

Shareholders can anticipate increased revenue visibility due to the substantial order book.

The company's strengthened global presence offers diversification benefits, reducing reliance on any single market.

Improved financial health, marked by positive operating cash flow and debt reduction, positions Fabtech for sustainable growth.

Risks to watch

Future performance remains subject to risks including fluctuations in revenue, income, and cash flows.

The successful implementation of its strategy and future growth levels are dependent on execution capabilities.

Performance is also susceptible to broader economic conditions in India and international markets, as well as industry trends and competition.

Peer comparison

Fabtech operates in the engineering, procurement, and construction (EPC) sector, a domain populated by major players. [cite:groundedResearch.companySnapshot[0]]

Peers such as Larsen & Toubro, KNR Constructions, and PNC Infratech also compete in various infrastructure and industrial segments. [cite:groundedResearch.peerSet[0], groundedResearch.peerSet[1], groundedResearch.peerSet[2]]

Fabtech's recent focus on specialized international projects and the animal health segment differentiates its strategic direction within this competitive landscape.

Context metrics (time-bound)

  • Consolidated Total Income grew by 28.4% from ₹335.94 Cr in FY25 to ₹431.33 Cr in FY26.
  • Consolidated EBITDA saw an increase of 18.29% from ₹46.97 Cr in FY25 to ₹55.56 Cr in FY26.
  • Consolidated Operating Cash Flow swung from -₹36.15 Cr in FY25 to ₹0.48 Cr in FY26.
  • Consolidated Current Borrowings decreased from ₹54.09 Cr in FY25 to ₹42.20 Cr in FY26.

What to track next

Monitor the progress and execution of large-scale pharma and infrastructure projects in Africa.

Watch for updates on expansion and execution in Saudi Arabia for vaccine and advanced pharma projects.

Track the timely completion of the North Africa veterinary facility targeted for Q1 FY27.

Observe continued revenue growth and market expansion initiatives in MENA, GCC, and ECO Zone markets.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.